Radiographic Erosions Research Articles

AB0219 Evaluation of the Japanese Patients with Rheumatoid Arthritis (RA) of RAPID Radiographic Progression (RRP) Treated with Synthetic Disease Modifying Anti-Rheumatic Drugs (DMARDS) in Daily Practice: A Large-Scale Prospective Longitudinal Cohort Study

BackgroundDisease modifying anti-rheumatic drugs (DMARDs) are known to inhibit radiographic progression in patients with rheumatoid arthritis (RA). However, there has been few epidemiological report of longitudinal radiographic progression in RA...

FRI0230 Exploring Cartilage Damage in Gout Using 3T Mri: Developing A Scoring System

BackgroundFew imaging studies have investigated cartilage damage in gout. Magnetic Resonance Imaging (MRI) can produce high quality images of cartilage damage in this disease and also reveal other features of...

AB1018 Articular Synovitis or Tenosynovitis - Which is More Involved toward Functional Disabilities in Patients with Rheumatoid Arthritis? Investigation of Wrist and Finger Joints by Ultrasound in Early-Stage Rheumatoid Arthritis

BackgroundBoth articular synovitis and tenosynovitis found by ultrasound (US) are representative findings in patients with rheumatoid arthritis (RA). These inflammatory changes appear to involve in functional disabilities of patients with...

SAT0186 Bone Mineral Density as A Predictor of Early Erosive Lesions in Rheumatoid Arthritis

BackgroundThe issues of early visualizing of the changes in the joints and bone which can be used as predictors of future joints structural damage are being discussed.ObjectivesTo assess changes in...

Interleukin‐17+CD8+ T Cells Are Enriched in the Joints of Patients With Psoriatic Arthritis and Correlate With Disease Activity and Joint Damage Progression

ObjectivePsoriatic arthritis (PsA) is associated with HLA class I genes, in contrast to the association with HLA class II in rheumatoid arthritis (RA). Since IL-17+ cells are considered important mediators of synovial inflammation, we sought to determine whether IL-17–producing CD8+ T cells may be found in the joints of patients with PsA and whether these cells might contribute to the disease process.MethodsMononuclear cells from paired samples of synovial fluid (SF) and peripheral blood (PB) from patients with PsA or patients with RA were stimulated ex vivo, and CD4− T cells were examined by flow cytometry for cytokine expression, cytotoxic markers, and frequencies of γ/δ or mucosal-associated invariant T cells. Clinical measures of arthritis activity (C-reactive protein [CRP] level, erythrocyte sedimentation rate [ESR], Disease Activity Score in 28 joints [DAS28]) and power Doppler ultrasound (PDUS) scores for the presence of active synovitis in the aspirated knee were recorded and assessed for correlations with immunologic markers.ResultsWithin the CD3+ T cell compartment, both IL-17+CD4− (predominantly CD8+) and IL-17+CD4+ T cells were significantly enhanced in the SF compared to the PB of patients with PsA (P = 0.0003 and P = 0.002, respectively; n = 21), whereas in patients with RA, only IL-17+CD4+ T cells were increased in the SF compared to the PB (P = 0.008; n = 14). The frequency of IL-17+CD4− T cells in PsA SF was positively correlated with the CRP level (r = 0.52, P = 0.01), ESR (r = 0.59, P = 0.004), and DAS28 (r = 0.52, P = 0.01), and was increased in patients with erosive disease (P < 0.05). In addition, the frequency of IL-17+CD4− T cells positively correlated with the PDUS score, a marker for active synovitis (r = 0.49, P = 0.04).ConclusionThese results show, for the first time, that the PsA joint, but not the RA joint, is enriched for IL-17+CD8+ T cells. Moreover, the findings reveal that the levels of this T cell subset are correlated with disease activity measures and the radiographic erosion status after 2 years, suggesting a previously unrecognized contribution of these cells to the pathogenesis of PsA.

The −308 G/A polymorphism in the tumor necrosis factor-α gene is not associated with development and progression of rheumatoid arthritis in Argentinean patients

A polymorphism in the tumor necrosis factor-alpha (TNF-α) promoter region has been associated with disease susceptibility and progression in rheumatoid arthritis (RA). The presence of an adenosine (TNF2 allele) instead of a guanine (TNF1 allele) at position -308 may be responsible for a general increase in the transcriptional activity of the TNF-α gene. Our aim was to evaluate the association of the TNF2 allele with the risk of disease development and/or progression of RA in an Argentine population cohort. Two hundred and twenty-three consecutive patients with RA according to the 1987 criteria of the American College of Rheumatology were included in the study. Clinical variables, Disease Activity Score 28, Health Assessment Questionnaire and Rheumatoid Arthritis Quality of Life were recorded. The radiographic erosions were determined by the method of Sharp/van der Heijde. A group of 111 healthy subjects matched by sex and age was used as a control. All samples were genotyped for the -308 G/A TNF-α polymorphism. No significant differences were observed either in the frequency of the TNF2 allele or in the genotypic distributions of the -308 G/A TNF-α polymorphism (P>0.05) between the control group and the RA patients. No association was found between the TNF2 allele and the variables related to the course and outcome of the disease (P>0.05). In this cohort of Argentinean patients with RA, the TNF2 allele was neither associated with susceptibility to the disease nor was it associated with the variables related to the course and outcome of the disease.

Relationship between structural joint damage and urate deposition in gout: a plain radiography and dual-energy CT study

ObjectivesThe aim of this work was to examine the relationship between joint damage and monosodium urate (MSU) crystal deposition in gout.MethodsPlain radiographs and dual-energy CT (DECT) scans of the feet...

Clinical Utility of Radiation Medicine 99mTc-Methylene Diphosphanate Bone Scintigraphy in the Early Diagnosis of Rheumatoid Arthritis.

The value of 99mTc-Methylene diphosphanate (99mTc-MDP) bone scan in predicting development of bony destruction, swelling, new bone erosions and skeletal deformities in small joints and bones was studied by visual evaluation of bone scans. 99m Tc-MDP was injected intravenously. 3 hours after the 99mTc-MDP injection, they have been underwent spot views of entire skeletons with planar scintigraphy in the anterior and posterior positions. All patients were examined under the Electronics Corporation of India Limited (ECIL) single head gamma camera imaging machine, equipped with a low-energy high-resolution parallel-hole collimator. In 9 patients with newly diagnosed rheumatoid arthritis a total of 60 patients of 99mTc-MDP bone scan were examined clinically, scintigraphically, and radiographically. The follow up period was 2 years. Seven patients found increased radiopharmaceutical increased in small joints. Onset of the rheumatoid disease was found in three out of seven patients. 2/9 patients, the joints which were eroded scintigraphically, was active at all the checkups. Erosions were detected earlier in foot joints than in finger joints. New erosions were especially prone to appear in joints with persisting and high scintigraphic activity. On the contrary, inactive joints by radionuclide scanning never eroded. Scintigraphic and clinical activity and radiographic erosion correlated significantly with each other. The sensitivity and specificity of visual scintigraphic assessment and the relative pixel activity method proved to be superior to the region of interest methods and clinical evaluation for prediction of bony erosions in patients of rheumatoid arthritis.

FRI0100 Treat to target: defining the optimum target to prevent radiographic erosion progression during the first year of treatment in an early rheumatoid arthritis cohort

BackgroundThe target for most treat to target (T2T) regimes in early rheumatoid arthritis (eRA) is DAS28 remission. However, power Doppler ultrasound (PDUS) activity in patients in DAS28 remission is associated...

AB0293 Changes in glucocorticoid treatment in the first year of biological therapy in RA patients

BackgroundGlucocorticoids (GC) are very commonly used in the rheumatoid arthritis (RA) treatment; however their potential risks warrants a rational use. 1,2ObjectivesEvaluate the impact of biological therapies on GC use in...

FRI0130 Change in disease outcomes after implementation of treat to target, including evaluation of power doppler ultrasound remission

BackgroundThe 2010 treatment to target guidelines recommend frequent assessment to achieve a pre-defined target (ideally remission) in early rheumatoid arthritis (RA) [1]. Power Doppler (PD) ultrasound has the ability to...

AB0362 Tight control of disease activity by conventional DMARDs could minimize the use of biological therapies in patients with early rheumatoid arthritis: Data from an early arthritis clinic in hong kong

ObjectivesTo examine the treatment outcome at 1 year of patients treated with tight control of the disease in a prospective cohort of patients with newly diagnosed rheumatoid arthritis (RA).MethodsAll patients...

OP0041 Tocilizumab (TCZ) in Combination and Monotherapy Versus Methotrexate (MTX) in MTX-Naive Patients (PTS) with Early Rheumatoid Arthritis (RA): Clinical and Radiographic Outcomes from a Randomised, Placebo-Controlled Trial

BackgroundRecent recommendations support intensive treatment of pts with early RA to achieve remission or low disease activity.1-3 TCZ was not previously studied exclusively in an early RA population.ObjectivesTo assess the...

AB0586 Role of particular class i mhc genotypes and haplotypes in determining different traits within the psoriatic arthritis phenotypes

BackgroundA rigorously ascertained psoriatic arthritis (PsA) cohort demonstrated considerable genetic heterogeneity and provided preliminary evidence that MHC genes determine quantitative traits within the PsA phenotype with different patterns of MHC...

THU0461-HPR Global assessment of disease by the patient in the new ACR/EULAR remission criteria: Why do not fulfil the remission?

BackgroundRecently, new criteria has been described for assessing Rheumatoid Arthritis (RA) remission. However, in clinical practice, patients who may be in remission by these criteria (ACR/EULAR 2011), ofter fail to...

OP0133 Analysis of Potential Predictors for Remission in Early Rheumatoid Arthritis According to ACR/EULAR Boolean, DAS28 and RAPID3RJ1 Criteria: Results from the Espoir Cohort

BackgroundRemission in rheumatoid arthritis (RA) is increasingly possible in recent years with a treat-to-target strategy. It would be of value to recognize baseline variables that are potential predictors of remission.ObjectivesTo...

FRI0146 Levels of ultrasensitive troponin and nt-probnp in rheumatoid arthritis

BackgroundPatients with rheumatoid arthritis (RA) experience premature mortality that is largely due to cardiovascular disease (CVD). Selective biomarkers have been proposed for CVD prediction. Indeed, ultrasensitive troponin (hs-cTn), a biomarker...

THU0414 Determination and quantification of synovial inflammation by magnetic resonance imaging in systemic sclerosis

BackgroundMagnetic resonance imaging (MRI) is useful method for detection and quantification of subclinical synovial inflammation and joint damage with better precision than radiography in systemic sclerosis (SSc). Early aggressive treatment...

FRI0127 Subcutaneous nodules in rheumatoid arthritis: Insights from a large multinational cohort

BackgroundSubcutaneous nodules (SCN) are easily identifiable extra-articular manifestation of rheumatoid arthritis (RA) with characteristic histopathology. Identifying clinical characteristics associated with SCN may lead to better pathophysiological understanding of RA, and...

AB0583 Effectiveness and safety of short-term treatment of active rheumatoid arthritis (RA) moderate to severe with tocilizumab

ObjectivesTo evaluate the effectiveness and safety of tocilizumab (TCZ) for the treatment of active RA in our department.MethodsType of study: Prospective cohort. Inclusion criteria: RA-patients (new ACR-EULAR criteria) who have...